clinical

Articles

Bradley Smith, MD, presents at AAO 2020 on how fingolimod 0.5 mg, a first-line treatment for multiple sclerosis, may reduce both the number of relapses and disease progression in patients with relapsing-remitting MS as well as the incidence of uveitis.

AAO 2020: Fingolimod for MS offers disease control with no development of uveitis

Videos

Glenn J. Jaffe, MD, presents a summary of the results of a confirmatory study on a previous Phase III trial that examined sustained drug delivery for the treatment of uveitis, as well as data on the 36-month results in the second, confirmatory phase 3 study of YUTIQ.

AAO 2020: Study confirms Phase III results for uveitis treatment

Chronic cases can be difficult for retina specialists; treatment is satisfying.

Noninfectious uveitis: Meeting the challenge

Cheryl Guttman Krader is a contributor to Dermatology Times, Ophthalmology Times, and Urology Times.

Look for clues to simplify anterior uveitis diagnosis

Inhibition plays role in autoimmune-based inflammation; has unique mechanism of action

Ongoing study evaluates sirolimus as therapeutic option for uveitis 

One biologic response modifier has indication for uveitis; several in development to gain FDA approval

Biologics may offer systemic therapy option for uveitis  

Quiescence, steroid-free quiescence achieved in VISUAL III trial

Adalimumab efficacious for uveitis regardless of disease duration

FA implant effective in lowering recurrence rates through available 6, 12 months of follow-up

Sustained-release corticosteroid expands armamentarium for uveitis 

Improvement in visual acuity, central retinal thickness, vitreous haze reported at 6 months

Tocilizumab effective for managing posterior segment inflammation

Intravitreal triamcinolone acetonide, dexamethasone implant superior for regional treatment of disorder

Uveitis